



## Clinical trial results: A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors Summary

EudraCT number	2015-002934-32
Trial protocol	NL BE PL
Global end of trial date	28 March 2023

### Results information

Result version number	v1 (current)
This version publication date	01 December 2023
First version publication date	01 December 2023

### Trial information

#### Trial identification

Sponsor protocol code	D4884C00001
-----------------------	-------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02527434
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	City House,132 Hills Road, Cambridge, United Kingdom, CB2 1RY
Public contact	Global Clinical Lead, AstraZeneca, +1 302 885 1180, ClinicalTrialTransparency@astrazeneca.com
Scientific contact	Global Clinical Lead, AstraZeneca, +1 302 885 1180, ClinicalTrialTransparency@astrazeneca.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 December 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	17 February 2018
Global end of trial reached?	Yes
Global end of trial date	28 March 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To investigate the efficacy and safety of tremelimumab monotherapy, with subsequent treatment with either durvalumab monotherapy or durvalumab + tremelimumab combination therapy in patients with select advanced solid tumors.

Protection of trial subjects:

This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council for Harmonisation/Good Clinical Practice, applicable regulatory requirements and the AstraZeneca policy on Bioethics.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 November 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 12
Country: Number of subjects enrolled	Korea, Republic of: 32
Country: Number of subjects enrolled	United States: 11
Country: Number of subjects enrolled	Poland: 3
Country: Number of subjects enrolled	Netherlands: 6
Worldwide total number of subjects	64
EEA total number of subjects	21

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	35
From 65 to 84 years	28
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

A total of 64 patients with select advanced solid tumors were treated in this phase II, open-label, multi-center study from November 2015. Primary data cut off date: 17 February 2018. Final data cut off date: 31 December 2018.

### Pre-assignment

Screening details:

The patients were split into 3 different analysis cohorts based on their tumor types: urothelial bladder cancer (UBC), triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC).

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	UBC Cohort

Arm description:

Patients with UBC entered the initial tremelimumab monotherapy phase and were administered tremelimumab for up to a total of 12 months or until confirmed progressive disease (PD). Eligible patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were given the option for retreatment with tremelimumab monotherapy or to be sequenced to receive MEDI4736 (durvalumab) + tremelimumab combination therapy (also referred to as COMBO) for up to a total of 8 months or to receive durvalumab monotherapy (also referred to as MEDI) for up to a total of 12 months.

Arm type	Experimental
Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Retreatment Phase (MEDI): Durvalumab 1.5 g via IV infusion q4w for up to a total of 12 months (13 doses).

Retreatment Phase (COMBO): Durvalumab 1.5 g via IV infusion q4w (in combination with tremelimumab 75 mg) for up to 4 doses, followed by durvalumab 1.5 g via IV infusion q4w for up to a total of 8 months (9 additional doses).

Investigational medicinal product name	Tremelimumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Monotherapy Phase: Tremelimumab 750 milligrams (mg) via intravenous (IV) infusion once every 4 weeks (q4w) for 7 doses (cycles), then every 12 weeks (q12w) for 2 additional cycles for up to a total of 12 months or until confirmed PD.

Retreatment Phase (COMBO): Tremelimumab 75 mg via IV infusion q4w for up to 4 doses (in combination with durvalumab 1.5 g).

<b>Arm title</b>	TNBC Cohort
------------------	-------------

**Arm description:**

Patients with TNBC entered the initial tremelimumab monotherapy phase and were administered tremelimumab for up to a total of 12 months or until confirmed PD. Eligible patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were given the option for retreatment with tremelimumab monotherapy or to be sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO) for up to a total of 8 months or to receive durvalumab monotherapy (also referred to as MEDI) for up to a total of 12 months.

Arm type	Experimental
Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Retreatment Phase (COMBO): Durvalumab 1.5 g via IV infusion q4w (in combination with tremelimumab 75 mg) for up to 4 doses, followed by durvalumab 1.5 g via IV infusion q4w for up to a total of 8 months (9 additional doses).

Investigational medicinal product name	Tremelimumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Monotherapy Phase: Tremelimumab 750 mg via IV infusion q4w for 7 doses, then q12w for 2 additional doses for up to a total of 12 months or until confirmed PD.

Retreatment Phase (COMBO): Tremelimumab 75 mg via IV infusion q4w for up to 4 doses (in combination with durvalumab 1.5 g).

<b>Arm title</b>	PDAC Cohort
------------------	-------------

**Arm description:**

Patients with PDAC entered the initial tremelimumab monotherapy phase and were administered tremelimumab for up to a total of 12 months or until confirmed PD. Eligible patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were given the option for retreatment with tremelimumab monotherapy or to be sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO) for up to a total of 8 months or to receive durvalumab monotherapy (also referred to as MEDI) for up to a total of 12 months.

Arm type	Experimental
Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Retreatment Phase (MEDI): Durvalumab 1.5 g via IV infusion q4w for up to a total of 12 months (13 doses).

Retreatment Phase (COMBO): Durvalumab 1.5 g via IV infusion q4w (in combination with tremelimumab 75 mg) for up to 4 doses, followed by durvalumab 1.5 g via IV infusion q4w for up to a total of 8 months (9 additional doses).

Investigational medicinal product name	Tremelimumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Monotherapy Phase: Tremelimumab 750 mg via IV infusion q4w for 7 doses, then q12w for 2 additional doses for up to a total of 12 months or until confirmed PD.

Retreatment Phase (COMBO): Tremelimumab 75 mg via IV infusion q4w for up to 4 doses (in combination with durvalumab 1.5 g).

<b>Number of subjects in period 1</b>	UBC Cohort	TNBC Cohort	PDAC Cohort
Started	32	12	20
Started Retreatment Phase (COMBO)	7	5	4
Started Retreatment Phase (MEDI)	4	0 <sup>[1]</sup>	1
Completed	4	1	0
Not completed	28	11	20
Consent withdrawn by subject	5	3	3
Death	19	6	17
Reason Not Specified	1	-	-
Lost to follow-up	2	2	-
Site closure	1	-	-

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No patients in this arm received MEDI in the retreatment phase.

## Baseline characteristics

### Reporting groups

Reporting group title	UBC Cohort
Reporting group description:	
Patients with UBC entered the initial tremelimumab monotherapy phase and were administered tremelimumab for up to a total of 12 months or until confirmed progressive disease (PD). Eligible patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were given the option for retreatment with tremelimumab monotherapy or to be sequenced to receive MEDI4736 (durvalumab) + tremelimumab combination therapy (also referred to as COMBO) for up to a total of 8 months or to receive durvalumab monotherapy (also referred to as MEDI) for up to a total of 12 months.	
Reporting group title	TNBC Cohort
Reporting group description:	
Patients with TNBC entered the initial tremelimumab monotherapy phase and were administered tremelimumab for up to a total of 12 months or until confirmed PD. Eligible patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were given the option for retreatment with tremelimumab monotherapy or to be sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO) for up to a total of 8 months or to receive durvalumab monotherapy (also referred to as MEDI) for up to a total of 12 months.	
Reporting group title	PDAC Cohort
Reporting group description:	
Patients with PDAC entered the initial tremelimumab monotherapy phase and were administered tremelimumab for up to a total of 12 months or until confirmed PD. Eligible patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were given the option for retreatment with tremelimumab monotherapy or to be sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO) for up to a total of 8 months or to receive durvalumab monotherapy (also referred to as MEDI) for up to a total of 12 months.	

Reporting group values	UBC Cohort	TNBC Cohort	PDAC Cohort
Number of subjects	32	12	20
Age Categorical			
Units: Subjects			
<=18 years	0	0	0
Between 18 and 65 years	13	8	14
>=65 years	19	4	6
Age continuous			
Units: years			
arithmetic mean	64.8	58.2	59.4
standard deviation	± 8.81	± 13.16	± 8.24
Sex: Female, Male			
Units: Subjects			
Female	6	12	9
Male	26	0	11
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	10	11	11
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	1
White	21	1	8
More than one race	0	0	0
Unknown or Not Reported	1	0	0

Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1	0	0
Not Hispanic or Latino	31	12	20
Unknown or Not Reported	0	0	0

<b>Reporting group values</b>	Total		
Number of subjects	64		
Age Categorical			
Units: Subjects			
<=18 years	0		
Between 18 and 65 years	35		
>=65 years	29		
Age continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Subjects			
Female	27		
Male	37		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	32		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	1		
White	30		
More than one race	0		
Unknown or Not Reported	1		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1		
Not Hispanic or Latino	63		
Unknown or Not Reported	0		



## End points

### End points reporting groups

Reporting group title	UBC Cohort
Reporting group description: Patients with UBC entered the initial tremelimumab monotherapy phase and were administered tremelimumab for up to a total of 12 months or until confirmed progressive disease (PD). Eligible patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were given the option for retreatment with tremelimumab monotherapy or to be sequenced to receive MEDI4736 (durvalumab) + tremelimumab combination therapy (also referred to as COMBO) for up to a total of 8 months or to receive durvalumab monotherapy (also referred to as MEDI) for up to a total of 12 months.	
Reporting group title	TNBC Cohort
Reporting group description: Patients with TNBC entered the initial tremelimumab monotherapy phase and were administered tremelimumab for up to a total of 12 months or until confirmed PD. Eligible patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were given the option for retreatment with tremelimumab monotherapy or to be sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO) for up to a total of 8 months or to receive durvalumab monotherapy (also referred to as MEDI) for up to a total of 12 months.	
Reporting group title	PDAC Cohort
Reporting group description: Patients with PDAC entered the initial tremelimumab monotherapy phase and were administered tremelimumab for up to a total of 12 months or until confirmed PD. Eligible patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were given the option for retreatment with tremelimumab monotherapy or to be sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO) for up to a total of 8 months or to receive durvalumab monotherapy (also referred to as MEDI) for up to a total of 12 months.	
Subject analysis set title	UBC - Tremelimumab Monotherapy
Subject analysis set type	Full analysis
Subject analysis set description: Patients with UBC were administered tremelimumab via IV infusion at a dose of 750 mg q4w for 7 cycles, then q12w for 2 additional cycles, for up to a total of 12 months or until confirmed PD.	
Subject analysis set title	TNBC - Tremelimumab Monotherapy
Subject analysis set type	Full analysis
Subject analysis set description: Patients with TNBC were administered tremelimumab via IV infusion at a dose of 750 mg q4w for 7 cycles, then q12w for 2 additional cycles, for up to a total of 12 months or until confirmed PD.	
Subject analysis set title	PDAC - Tremelimumab Monotherapy
Subject analysis set type	Full analysis
Subject analysis set description: Patients with PDAC were administered tremelimumab via IV infusion at a dose of 750 mg q4w for 7 cycles, then q12w for 2 additional cycles, for up to a total of 12 months or until confirmed PD.	
Subject analysis set title	UBC - COMBO
Subject analysis set type	Sub-group analysis
Subject analysis set description: Eligible UBC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO; durvalumab 1.5 g via IV infusion q4w in combination with tremelimumab 75 mg via IV infusion q4w for up to 4 cycles each, followed by durvalumab 1.5 g via IV infusion q4w) for up to a total of 8 months.	
Subject analysis set title	TNBC - COMBO
Subject analysis set type	Sub-group analysis
Subject analysis set description: Eligible TNBC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO; durvalumab 1.5 g via IV infusion q4w in combination with tremelimumab 75 mg via IV infusion q4w for up to 4 cycles each, followed by durvalumab 1.5 g via IV infusion q4w) for up to a total of 8 months.	

Subject analysis set title	PDAC - COMBO
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Eligible PDAC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO; durvalumab 1.5 g via IV infusion q4w in combination with tremelimumab 75 mg via IV infusion q4w for up to 4 cycles each, followed by durvalumab 1.5 g via IV infusion q4w) for up to a total of 8 months.

Subject analysis set title	UBC- MEDI
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Eligible UBC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab monotherapy (also referred to as MEDI; 1.5 g via IV infusion q4w) for up to a total of 12 months.

Subject analysis set title	PDAC - MEDI
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Eligible PDAC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab monotherapy (also referred to as MEDI; 1.5 g via IV infusion q4w) for up to a total of 12 months.

### Primary: Percentage of Patients with Confirmed Overall Response during Tremelimumab Monotherapy Phase

End point title	Percentage of Patients with Confirmed Overall Response during Tremelimumab Monotherapy Phase <sup>[1]</sup>
-----------------	---

End point description:

Objective response rate (ORR) during the initial tremelimumab monotherapy phase was assessed by the site Investigator using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) and was defined as the percentage of patients with a confirmed overall response of complete response (CR) or partial response (PR) and was based on all treated patients who had measurable disease at baseline (Day 1). 95% confidence intervals (CIs) were calculated using the Clopper Pearson method. Analysis was performed on the Full Analysis Set (FAS) (all treated patients who received at least 1 dose of tremelimumab monotherapy).

End point type	Primary
----------------	---------

End point timeframe:

From baseline to 12 months in the tremelimumab monotherapy phase

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: In accordance with the protocol, no comparative analyses were performed.

End point values	UBC - Tremelimumab Monotherapy	TNBC - Tremelimumab Monotherapy	PDAC - Tremelimumab Monotherapy	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	32	12	20	
Units: Percentage of Patients				
number (confidence interval 95%)	18.8 (7.2 to 36.4)	8.3 (0.2 to 38.5)	0.0 (0.0 to 16.8)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Median Duration of Response (DoR) during Tremelimumab Monotherapy

## Phase

End point title	Median Duration of Response (DoR) during Tremelimumab Monotherapy Phase
-----------------	---

End point description:

DoR during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the progression-free survival (PFS) censoring time. Analysis was performed on the FAS (all treated patients who received at least 1 dose of tremelimumab monotherapy). DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to 12 months in the tremelimumab monotherapy phase

End point values	UBC - Tremelimumab Monotherapy	TNBC - Tremelimumab Monotherapy	PDAC - Tremelimumab Monotherapy	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	6 <sup>[2]</sup>	1	0 <sup>[3]</sup>	
Units: Months				
median (inter-quartile range (Q1-Q3))	999999.99 (999999.99 to 999999.99)	12.9 (12.9 to 12.9)	( to )	

Notes:

[2] - 999999.99 = data not estimable

[3] - As no patients had a documented response, no DoR could be calculated.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Disease Control Rate (DCR) during Tremelimumab Monotherapy Phase

End point title	Disease Control Rate (DCR) during Tremelimumab Monotherapy Phase
-----------------	--

End point description:

DCR during the initial tremelimumab monotherapy phase was defined as the percentage of patients who had a best objective response (BoR) of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) and 12 months (all patients), or who had demonstrated stable disease (SD) for a minimum interval of 3, 4 or 12 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method. Analysis was performed on the FAS (all treated patients who received at least 1 dose of tremelimumab monotherapy).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to 12 months in the tremelimumab monotherapy phase

End point values	UBC - Tremelimumab Monotherapy	TNBC - Tremelimumab Monotherapy	PDAC - Tremelimumab Monotherapy	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	32	12	20	
Units: Percentage of patients				
number (confidence interval 95%)				
DCR at 3 or 4 months	25.0 (11.46 to 43.40)	8.3 (0.21 to 38.48)	0.0 (0.00 to 16.84)	
DCR at 12 months	21.9 (9.28 to 39.97)	8.3 (0.21 to 38.48)	0.0 (0.00 to 16.84)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Median PFS during Tremelimumab Monotherapy Phase

End point title	Median PFS during Tremelimumab Monotherapy Phase
End point description:	
PFS during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique. Analysis was performed on the FAS (all treated patients who received at least 1 dose of tremelimumab monotherapy).	
End point type	Secondary
End point timeframe:	
From baseline to 12 months in the tremelimumab monotherapy phase	

End point values	UBC - Tremelimumab Monotherapy	TNBC - Tremelimumab Monotherapy	PDAC - Tremelimumab Monotherapy	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	32 <sup>[4]</sup>	12	20	
Units: Months				
median (inter-quartile range (Q1-Q3))	2.63 (1.77 to 999999.99)	3.58 (1.40 to 4.04)	1.77 (1.38 to 2.92)	

Notes:

[4] - 999999.99 = data not estimable

## Statistical analyses

No statistical analyses for this end point

### Secondary: Best Objective Response (BoR) during Tremelimumab Monotherapy Phase

End point title	Best Objective Response (BoR) during Tremelimumab Monotherapy Phase
-----------------	---

---

**End point description:**

BoR during the initial tremelimumab monotherapy phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or not evaluable [NE]) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE). Analysis was performed on the FAS (all treated patients who received at least 1 dose of tremelimumab monotherapy).

---

End point type	Secondary
----------------	-----------

---

**End point timeframe:**

From baseline to 12 months in the tremelimumab monotherapy phase

---

End point values	UBC - Tremelimumab Monotherapy	TNBC - Tremelimumab Monotherapy	PDAC - Tremelimumab Monotherapy	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	32	12	20	
Units: Percentage of Patients				
number (not applicable)				
CR	6.3	0.0	0.0	
PR	12.5	8.3	0.0	
SD	9.4	0.0	0.0	
PD	68.8	91.7	90.0	
NE	3.1	0.0	10.0	

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Median Overall Survival (OS) during Tremelimumab Monotherapy Phase**

---

End point title	Median Overall Survival (OS) during Tremelimumab Monotherapy Phase
-----------------	--

---

**End point description:**

OS was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. OS is presented from start of tremelimumab monotherapy phase and includes the retreatment phase if the patient entered the corresponding treatment phase. Median OS was calculated using the Kaplan-Meier technique. Analysis was performed on the FAS (all treated patients who received at least 1 dose of tremelimumab monotherapy).

---

End point type	Secondary
----------------	-----------

---

**End point timeframe:**

From baseline to primary data cut-off date

---

End point values	UBC - Tremelimumab Monotherapy	TNBC - Tremelimumab Monotherapy	PDAC - Tremelimumab Monotherapy	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	32	12 <sup>[5]</sup>	20	
Units: Months				
median (confidence interval 95%)	10.32 (5.91 to 24.61)	12.88 (2.53 to 999999.99)	3.98 (2.83 to 5.13)	

Notes:

[5] - 999999.99 = data not estimable

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Patients with Confirmed Overall Response during Retreatment Phase

End point title	Percentage of Patients with Confirmed Overall Response during Retreatment Phase
-----------------	---

End point description:

ORR was assessed by the site Investigator using RECIST 1.1 and was defined as the percentage of patients with a confirmed overall response of CR or PR and was based on all treated patients who had measurable disease at baseline (Day 1) and who sequenced to durvalumab monotherapy (MEDI treatment phase) or durvalumab + tremelimumab combination therapy (COMBO treatment phase). 95% CIs were calculated using the Clopper Pearson method. Analysis was performed on the MEDI and COMBO analysis sets (all patients who were treated with tremelimumab, received at least 1 dose of durvalumab monotherapy or durvalumab + tremelimumab combination therapy as applicable, and who had a baseline tumor assessment prior to dosing).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to 12 months in retreatment phase

End point values	UBC - COMBO	TNBC - COMBO	PDAC - COMBO	UBC- MEDI
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	5	4	4
Units: Percentage of Patients				
number (confidence interval 95%)	0.0 (0.0 to 41.0)	0.0 (0.0 to 52.2)	0.0 (0.0 to 60.2)	25.0 (0.6 to 80.6)

End point values	PDAC - MEDI			
Subject group type	Subject analysis set			
Number of subjects analysed	1			
Units: Percentage of Patients				
number (confidence interval 95%)	0.0 (0.0 to 97.5)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Median DoR during Retreatment Phase

End point title	Median DoR during Retreatment Phase
-----------------	-------------------------------------

End point description:

DoR during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the PFS censoring time. Analysis was performed on the MEDI and COMBO analysis sets (all patients who were treated with tremelimumab, received at least 1 dose of durvalumab monotherapy or durvalumab + tremelimumab combination therapy as applicable, and who had a baseline tumor assessment prior to dosing). DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to 12 months in retreatment phase

End point values	UBC - COMBO	TNBC - COMBO	PDAC - COMBO	UBC- MEDI
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	0 <sup>[6]</sup>	0 <sup>[7]</sup>	0 <sup>[8]</sup>	1
Units: Months				
median (inter-quartile range (Q1-Q3))	( to )	( to )	( to )	7.3 (7.3 to 7.3)

Notes:

[6] - As no patients had a documented response, no DoR could be calculated.

[7] - As no patients had a documented response, no DoR could be calculated.

[8] - As no patients had a documented response, no DoR could be calculated.

End point values	PDAC - MEDI			
Subject group type	Subject analysis set			
Number of subjects analysed	0 <sup>[9]</sup>			
Units: Months				
median (inter-quartile range (Q1-Q3))	( to )			

Notes:

[9] - As no patients had a documented response, no DoR could be calculated.

## Statistical analyses

No statistical analyses for this end point

### Secondary: DCR during Retreatment Phase

End point title	DCR during Retreatment Phase
-----------------	------------------------------

End point description:

DCR during the retreatment phase was defined as the percentage of patients who had a BoR of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) or who had demonstrated SD for a minimum interval of 3 or 4 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method. Analysis was performed on the MEDI and COMBO analysis sets (all patients who were treated with tremelimumab, received at

least 1 dose of durvalumab monotherapy or durvalumab + tremelimumab combination therapy as applicable, and who had a baseline tumor assessment prior to dosing).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to 4 months in retreatment phase

End point values	UBC - COMBO	TNBC - COMBO	PDAC - COMBO	UBC- MEDI
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	5	4	4
Units: Percentage of Patients				
number (confidence interval 95%)				
Disease control at 3 or 4 months	28.6 (3.67 to 70.96)	20.0 (0.51 to 71.64)	25.0 (0.63 to 80.59)	25.0 (0.63 to 80.59)

End point values	PDAC - MEDI			
Subject group type	Subject analysis set			
Number of subjects analysed	1			
Units: Percentage of Patients				
number (confidence interval 95%)				
Disease control at 3 or 4 months	0.0 (0.00 to 97.50)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Median PFS during Retreatment Phase

End point title	Median PFS during Retreatment Phase
-----------------	-------------------------------------

End point description:

PFS during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique. Analysis was performed on the MEDI and COMBO analysis sets (all patients who were treated with tremelimumab, received at least 1 dose of durvalumab monotherapy or durvalumab + tremelimumab combination therapy as applicable, and who had a baseline tumor assessment prior to dosing).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to 12 months in retreatment phase



End point values	UBC - COMBO	TNBC - COMBO	PDAC - COMBO	UBC- MEDI
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	5 <sup>[10]</sup>	4	4
Units: Months				
median (inter-quartile range (Q1-Q3))	2.83 (1.81 to 3.65)	0.99 (0.92 to 999999.99)	2.86 (1.87 to 3.52)	2.86 (1.81 to 6.62)

Notes:

[10] - 999999.99 = data not estimable

End point values	PDAC - MEDI			
Subject group type	Subject analysis set			
Number of subjects analysed	1			
Units: Months				
median (inter-quartile range (Q1-Q3))	1.84 (1.84 to 1.84)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: BoR during Retreatment Phase

End point title	BoR during Retreatment Phase
-----------------	------------------------------

End point description:

BoR during the retreatment phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or NE) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE). Analysis was performed on the MEDI and COMBO analysis sets (all patients who were treated with tremelimumab, received at least 1 dose of durvalumab monotherapy or durvalumab + tremelimumab combination therapy as applicable, and who had a baseline tumor assessment prior to dosing).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to 12 months in retreatment phase

End point values	UBC - COMBO	TNBC - COMBO	PDAC - COMBO	UBC- MEDI
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	5	4	4
Units: Percentage of Patients				
number (not applicable)				
CR	0.0	0.0	0.0	0.0
PR	0.0	0.0	0.0	25.0
SD	14.3	20.0	0.0	0.0
PD	71.4	80.0	100.0	75.0
NE	14.3	0.0	0.0	0.0

End point values	PDAC - MEDI			
Subject group type	Subject analysis set			
Number of subjects analysed	1			
Units: Percentage of Patients				
number (not applicable)				
CR	0.0			
PR	0.0			
SD	0.0			
PD	100.0			
NE	0.0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Median OS during Retreatment Phase

End point title	Median OS during Retreatment Phase
-----------------	------------------------------------

End point description:

OS during the retreatment phase was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. Analysis was performed on the MEDI and COMBO analysis sets (all patients who were treated with tremelimumab, received at least 1 dose of durvalumab monotherapy or durvalumab + tremelimumab combination therapy as applicable, and who had a baseline tumor assessment prior to dosing).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline in retreatment phase to primary data cut-off date

End point values	UBC - COMBO	TNBC - COMBO	PDAC - COMBO	UBC- MEDI
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7 <sup>[11]</sup>	5	4	4
Units: Months				
median (confidence interval 95%)	11.86 (5.91 to 999999.99)	33.05 (9.69 to 33.05)	7.18 (3.98 to 18.76)	16.53 (7.56 to 32.39)

Notes:

[11] - 999999.99 = data not estimable

End point values	PDAC - MEDI			
Subject group type	Subject analysis set			
Number of subjects analysed	1 <sup>[12]</sup>			
Units: Months				
median (confidence interval 95%)	4.14			

Notes:

[12] - 999999.99 = data not estimable

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected from Day 1 (i.e. first dose) up until 90 days following the end of treatment in the tremelimumab monotherapy phase and the retreatment phase (up to a total of 15 months per treatment phase).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	21.0

### Reporting groups

Reporting group title	TNBC - Tremelimumab Monotherapy
-----------------------	---------------------------------

Reporting group description:

Patients with TNBC were administered tremelimumab via IV infusion at a dose of 750 mg q4w for 7 cycles, then q12w for 2 additional cycles, for up to a total of 12 months or until confirmed PD.

Reporting group title	PDAC- Tremelimumab Monotherapy
-----------------------	--------------------------------

Reporting group description:

Patients with PDAC were administered tremelimumab via IV infusion at a dose of 750 mg q4w for 7 cycles, then q12w for 2 additional cycles, for up to a total of 12 months or until confirmed PD.

Reporting group title	UBC - COMBO
-----------------------	-------------

Reporting group description:

Eligible UBC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO; durvalumab 1.5 g via IV infusion q4w in combination with tremelimumab 75 mg via IV infusion q4w for up to 4 cycles each, followed by durvalumab 1.5 g via IV infusion q4w) for up to a total of 8 months.

Reporting group title	UBC- Tremelimumab Monotherapy
-----------------------	-------------------------------

Reporting group description:

Patients with UBC were administered tremelimumab via IV infusion at a dose of 750 mg q4w for 7 cycles, then q12w for 2 additional cycles, for up to a total of 12 months or until confirmed PD.

Reporting group title	UBC- MEDI
-----------------------	-----------

Reporting group description:

Eligible UBC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab monotherapy (also referred to as MEDI; 1.5 g via IV infusion q4w) for up to a total of 12 months.

Reporting group title	TNBC - COMBO
-----------------------	--------------

Reporting group description:

Eligible TNBC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO; durvalumab 1.5 g via IV infusion q4w in combination with tremelimumab 75 mg via IV infusion q4w for up to 4 cycles each, followed by durvalumab 1.5 g via IV infusion q4w) for up to a total of 8 months.

Reporting group title	PDAC - COMBO
-----------------------	--------------

Reporting group description:

Eligible PDAC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab + tremelimumab combination therapy (also referred to as COMBO; durvalumab 1.5 g via IV infusion q4w in combination with tremelimumab 75 mg via IV infusion q4w for up to 4 cycles each, followed by durvalumab 1.5 g via IV infusion q4w) for up to a total of 8 months.

Reporting group title	PDAC - MEDI
-----------------------	-------------

Reporting group description:

Eligible PDAC patients with confirmed PD on tremelimumab monotherapy or during the follow-up period were sequenced to receive durvalumab monotherapy (also referred to as MEDI; 1.5 g via IV infusion q4w) for up to a total of 12 months.

<b>Serious adverse events</b>	<b>TNBC - Tremelimumab Monotherapy</b>	<b>PDAC- Tremelimumab Monotherapy</b>	<b>UBC - COMBO</b>
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 12 (33.33%)	11 / 20 (55.00%)	3 / 7 (42.86%)
number of deaths (all causes)	4	12	4
number of deaths resulting from adverse events	1	1	0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Euthanasia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Malaise			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal			

disorders			
Dyspnoea			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea exertional			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			

subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuritis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune colitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Diarrhoea			
subjects affected / exposed	0 / 12 (0.00%)	3 / 20 (15.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct obstruction			



subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatotoxicity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypophysitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis bacterial			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	2 / 12 (16.67%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	UBC- Tremelimumab Monotherapy	UBC- MEDI	TNBC - COMBO
Total subjects affected by serious adverse events			
subjects affected / exposed	18 / 32 (56.25%)	1 / 4 (25.00%)	2 / 5 (40.00%)
number of deaths (all causes)	13	4	2
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Euthanasia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			

subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea exertional			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune colitis			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	3 / 32 (9.38%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			

subjects affected / exposed	4 / 32 (12.50%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	2 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct obstruction			

subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatotoxicity			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypophysitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis bacterial			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



<b>Serious adverse events</b>	PDAC - COMBO	PDAC - MEDI	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 4 (75.00%)	0 / 1 (0.00%)	
number of deaths (all causes)	4	1	
number of deaths resulting from adverse events	0	0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Euthanasia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuritis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune colitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			

subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal obstruction			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct obstruction			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatotoxicity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Hypophysitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis aseptic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis bacterial			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	<b>TNBC - Tremelimumab Monotherapy</b>	<b>PDAC- Tremelimumab Monotherapy</b>	<b>UBC - COMBO</b>
Total subjects affected by non-serious adverse events subjects affected / exposed	10 / 12 (83.33%)	19 / 20 (95.00%)	7 / 7 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Vascular disorders Hot flush subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Embolism subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	1 / 7 (14.29%) 1
Hypertension subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Lymphoedema subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Hypotension subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	1 / 7 (14.29%) 1
Vascular fragility subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
General disorders and administration site conditions Asthenia			

subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Face oedema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	1 / 12 (8.33%)	6 / 20 (30.00%)	2 / 7 (28.57%)
occurrences (all)	1	6	2
Influenza like illness			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Malaise			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Oedema peripheral			
subjects affected / exposed	0 / 12 (0.00%)	2 / 20 (10.00%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Oedema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	2 / 12 (16.67%)	2 / 20 (10.00%)	2 / 7 (28.57%)
occurrences (all)	3	2	3
Respiratory, thoracic and mediastinal disorders			
Dysphonia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Cough			
subjects affected / exposed	1 / 12 (8.33%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Oropharyngeal pain			



subjects affected / exposed	3 / 12 (25.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	3	2	0
Laryngospasm			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Laryngeal inflammation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	2 / 12 (16.67%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Dyspnoea			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Depressed mood			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Insomnia			
subjects affected / exposed	2 / 12 (16.67%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences (all)	2	0	1
Depression			
subjects affected / exposed	1 / 12 (8.33%)	2 / 20 (10.00%)	0 / 7 (0.00%)
occurrences (all)	1	2	0
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	0 / 12 (0.00%)	3 / 20 (15.00%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Amylase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	2 / 20 (10.00%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	2 / 20 (10.00%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Lipase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 12 (0.00%)	2 / 20 (10.00%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Injury, poisoning and procedural complications			
Procedural pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Radiation skin injury			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 12 (16.67%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences (all)	2	0	1
Facial paralysis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Dizziness			

subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Brain oedema subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	1 / 7 (14.29%) 1
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	1 / 7 (14.29%) 1
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	2 / 20 (10.00%) 3	2 / 7 (28.57%) 2
Febrile neutropenia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Ear and labyrinth disorders Ear discomfort subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Eye disorders Eyelid oedema subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 2	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	2 / 20 (10.00%) 2	0 / 7 (0.00%) 0
Abdominal pain			

subjects affected / exposed	2 / 12 (16.67%)	6 / 20 (30.00%)	1 / 7 (14.29%)
occurrences (all)	2	6	1
Abdominal pain upper			
subjects affected / exposed	2 / 12 (16.67%)	2 / 20 (10.00%)	0 / 7 (0.00%)
occurrences (all)	2	2	0
Anal inflammation			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Ascites			
subjects affected / exposed	1 / 12 (8.33%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Colitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	5 / 12 (41.67%)	3 / 20 (15.00%)	0 / 7 (0.00%)
occurrences (all)	5	3	0
Diarrhoea			
subjects affected / exposed	2 / 12 (16.67%)	4 / 20 (20.00%)	1 / 7 (14.29%)
occurrences (all)	3	7	1
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 12 (8.33%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Gastritis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	1 / 12 (8.33%)	4 / 20 (20.00%)	1 / 7 (14.29%)
occurrences (all)	1	4	1
Stomatitis			

subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	2 / 12 (16.67%)	2 / 20 (10.00%)	0 / 7 (0.00%)
occurrences (all)	2	2	0
Skin and subcutaneous tissue disorders			
Dermal cyst			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Dry skin			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Pain of skin			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Nail discolouration			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Papule			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	5 / 12 (41.67%)	7 / 20 (35.00%)	1 / 7 (14.29%)
occurrences (all)	5	7	1
Rash			
subjects affected / exposed	2 / 12 (16.67%)	5 / 20 (25.00%)	1 / 7 (14.29%)
occurrences (all)	2	6	1
Pruritus generalised			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Renal and urinary disorders			
Bladder spasm			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Acute kidney injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Haematuria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urinary tract pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Back pain			
subjects affected / exposed	0 / 12 (0.00%)	3 / 20 (15.00%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Muscular weakness			
subjects affected / exposed	1 / 12 (8.33%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Myalgia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

Spinal pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Infections and infestations			
Catheter site infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Oral infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Paronychia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Wound infection subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 2	0 / 20 (0.00%) 0	1 / 7 (14.29%) 1
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 2	5 / 20 (25.00%) 5	1 / 7 (14.29%) 1
Dehydration subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 20 (0.00%) 0	0 / 7 (0.00%) 0
Hyperglycaemia			

subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hyperkalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypernatraemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hyperuricaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Hypocalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 20 (5.00%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hypomagnesaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	2 / 12 (16.67%)	3 / 20 (15.00%)	0 / 7 (0.00%)
occurrences (all)	2	3	0
Hypophosphataemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 20 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	UBC- Tremelimumab Monotherapy	UBC- MEDI	TNBC - COMBO
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 32 (93.75%)	4 / 4 (100.00%)	5 / 5 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			



Tumour pain subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
Vascular disorders			
Hot flush subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
Embolism subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Hypertension subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Lymphoedema subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Hypotension subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 4 (0.00%) 0	2 / 5 (40.00%) 2
Vascular fragility subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Face oedema subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	15 / 32 (46.88%) 20	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
Malaise			

subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Oedema peripheral			
subjects affected / exposed	4 / 32 (12.50%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	4	0	0
Oedema			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	2	0	1
Pyrexia			
subjects affected / exposed	4 / 32 (12.50%)	1 / 4 (25.00%)	1 / 5 (20.00%)
occurrences (all)	4	1	5
Respiratory, thoracic and mediastinal disorders			
Dysphonia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Cough			
subjects affected / exposed	8 / 32 (25.00%)	0 / 4 (0.00%)	2 / 5 (40.00%)
occurrences (all)	9	0	2
Oropharyngeal pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	3
Laryngospasm			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Laryngeal inflammation			
subjects affected / exposed	0 / 32 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Productive cough			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	3 / 5 (60.00%)
occurrences (all)	0	0	3
Dyspnoea			

subjects affected / exposed	4 / 32 (12.50%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	5	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Delirium			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Depressed mood			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	3 / 32 (9.38%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	3	0	1
Depression			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Amylase increased			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	4	0	1
Blood creatinine increased			
subjects affected / exposed	1 / 32 (3.13%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Gamma-glutamyltransferase increased			

subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Lipase increased			
subjects affected / exposed	3 / 32 (9.38%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	4	0	0
Weight decreased			
subjects affected / exposed	4 / 32 (12.50%)	0 / 4 (0.00%)	2 / 5 (40.00%)
occurrences (all)	4	0	2
Injury, poisoning and procedural complications			
Procedural pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Radiation skin injury			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 32 (9.38%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	3	0	2
Facial paralysis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Brain oedema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Presyncope			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	7 / 32 (21.88%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	9	0	1
Febrile neutropenia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Eyelid oedema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	2	0	1
Abdominal distension			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	4 / 32 (12.50%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	4	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Anal inflammation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Colitis			

subjects affected / exposed	4 / 32 (12.50%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	4	0	0
Constipation			
subjects affected / exposed	9 / 32 (28.13%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	9	0	1
Diarrhoea			
subjects affected / exposed	8 / 32 (25.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	9	0	2
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	3 / 32 (9.38%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	4	0	1
Gastritis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Haematochezia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	11 / 32 (34.38%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	13	0	1
Stomatitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	4 / 32 (12.50%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	5	0	1
Skin and subcutaneous tissue disorders			
Dermal cyst			
subjects affected / exposed	0 / 32 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Blister			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Dry skin			
subjects affected / exposed	5 / 32 (15.63%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	5	0	0
Pain of skin			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nail discolouration			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Papule			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	8 / 32 (25.00%)	0 / 4 (0.00%)	2 / 5 (40.00%)
occurrences (all)	9	0	2
Rash			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	3	0	1
Pruritus generalised			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Rash maculo-papular			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	3	0	0
Renal and urinary disorders			
Bladder spasm			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Acute kidney injury			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	2	0	1
Dysuria			
subjects affected / exposed	1 / 32 (3.13%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Haematuria			

subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Urinary tract pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 5	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1
Spinal pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Infections and infestations Catheter site infection subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1
Oral infection subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Paronychia			



subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	2 / 32 (6.25%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Rhinitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Wound infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	4 / 32 (12.50%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	4	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	7 / 32 (21.88%)	0 / 4 (0.00%)	4 / 5 (80.00%)
occurrences (all)	9	0	4
Dehydration			
subjects affected / exposed	4 / 32 (12.50%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	4	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	6 / 32 (18.75%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	6	1	0
Hyperkalaemia			
subjects affected / exposed	1 / 32 (3.13%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
Hypernatraemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0

Hypoalbuminaemia subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 7	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Hypomagnesaemia subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 4	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Hyponatraemia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 4 (0.00%) 0	2 / 5 (40.00%) 2
Hypophosphataemia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0

<b>Non-serious adverse events</b>	PDAC - COMBO	PDAC - MEDI	
Total subjects affected by non-serious adverse events subjects affected / exposed	4 / 4 (100.00%)	1 / 1 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Vascular disorders Hot flush subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Embolism subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 1 (0.00%) 0	
Hypertension subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Lymphoedema			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypotension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Vascular fragility			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 4 (50.00%)	1 / 1 (100.00%)	
occurrences (all)	2	1	
Face oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Influenza like illness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Malaise			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Non-cardiac chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Oedema peripheral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Oedema			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Pyrexia			

subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 1 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Dysphonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Cough			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Laryngospasm			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Laryngeal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Productive cough			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pulmonary embolism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Delirium			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Depressed mood			

subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Insomnia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Depression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Amylase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blood creatinine increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Lipase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Injury, poisoning and procedural complications			
Procedural pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Radiation skin injury			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Facial paralysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dizziness			
subjects affected / exposed	0 / 4 (0.00%)	1 / 1 (100.00%)	
occurrences (all)	0	1	
Brain oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Presyncope			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Febrile neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Vertigo			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Eye disorders			

Eyelid oedema subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Abdominal distension subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Abdominal pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 1 (0.00%) 0	
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Anal inflammation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Ascites subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Colitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Constipation subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 1 (0.00%) 0	
Diarrhoea subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 1 (0.00%) 0	
Diarrhoea haemorrhagic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Dyspepsia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Gastritis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Haematochezia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Vomiting			
subjects affected / exposed	1 / 4 (25.00%)	1 / 1 (100.00%)	
occurrences (all)	3	1	
Skin and subcutaneous tissue disorders			
Dermal cyst			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blister			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dry skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pain of skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Nail discolouration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Papule			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	



Pruritus			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Rash			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Pruritus generalised			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Rash maculo-papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Renal and urinary disorders			
Bladder spasm			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Acute kidney injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dysuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Haematuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Urinary tract pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypothyroidism			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Muscular weakness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Spinal pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Catheter site infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Oral infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Paronychia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Rhinitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Wound infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Urinary tract infection			

subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Dehydration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hyperkalaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypernatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hyperuricaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypoalbuminaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Hypocalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypokalaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	3	0	
Hypomagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Hyponatraemia			
subjects affected / exposed	2 / 4 (50.00%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Hypophosphataemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 May 2016	<ul style="list-style-type: none"><li>• Inclusion criteria revised to permit evaluation of durvalumab in a broader UBC patient population.</li><li>• Exclusion criteria revised to exclude patients who had participated in prior durvalumab /tremelimumab studies and permit inclusion of patients with brain metastases or spinal cord compression.</li><li>• Timeline of major surgical procedure (as defined by the Investigator) prior to the first dose of investigational product was changed from 21 days to 28 days.</li></ul>
25 January 2018	<ul style="list-style-type: none"><li>• Data cut-off (DCO) date for the primary analysis was updated to reflect the latest status of clinical study progression.</li><li>• Information in protocol revised based on updated DCO.</li></ul>
13 September 2018	<ul style="list-style-type: none"><li>• Final DCO of OS and safety after primary analysis updated.</li><li>• Information in protocol revised based on final DCO.</li><li>• To update patient management and treatment options after final DCO.</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported